TEST BANK
Rau's Respiratory Care Pharmacology 11th
Edition by Douglas S. Gardenhire.
Breathe Easy: Master Respiratory Pharmacology with the Complete Test Bank!
Elevate your respiratory therapy expertise with the Test Bank for Rau's Respiratory Care Pharmacology, 11th
Edition by Douglas S. Gardenhire. This gold-standard resource covers ALL 22 Chapters, delivering exam-ready
practice aligned with the latest FDA approvals, COVID-19 insights, and clinical connections—essential for CRT,
RRT, or NBRC TMC/HM exam success.
Stop guessing and start excelling! Our 450+ page digital PDF unleashes over 2,000 questions in NBRC-style formats:
multiple-choice, true/false, calculations, and case-based scenarios that test real-world application. From foundational
principles in Unit I (Chapters 1-5: Introduction to Pharmacology, Drug Actions, Aerosol Delivery, Dose Calculations,
and Nervous Systems) to core respiratory treatments in Unit II (Chapters 6-12: Bronchodilators, Anticholinergics,
Corticosteroids, Mucokinetics, and more) and critical care in Unit III (Chapters 13-22: Sedatives, Analgesics,
Antihypertensives, Antimicrobials, and Neonatal/Pediatric Drugs), every section sharpens your skills. Each question
includes detailed rationales, correct/incorrect explanations, and page references to clarify complex topics like
surfactant therapy (Chapter 21) or neuromuscular blockers (Chapter 19).
,Description
Test Bank for Rau’s Respiratory Care Pharmacology 11th Edition Gardenhire
Test Bank for Rau’s Respiratory Care Pharmacology, 11th Edition, Gardenhire, ISBN-
10:0323871550, ISBN-13: 978-0323871556
Table of Contents
Unit I: Basic Concepts and Principles in Pharmacology
1. Introduction to Respiratory Care Pharmacology
2. Principles of Drug Action
3. Administration of Aerosolized Agents
4. Calculating Drug Doses
5. The Central and Peripheral Nervous Systems
Unit II: Drugs Used to Treat the Respiratory System
6. Adrenergic (Sympathomimetic) Bronchodilators
7. Anticholinergic (Parasympatholytic) Bronchodilators
8. Xanthines
9. Mucus-Controlling Drug Therapy
10. Surfactant Agents
11. Corticosteriods in Respiratory Care
12. Nonsteroidal Antiasthma Agents
13. Aerosolized Antiinfective Agents
14. Antimicrobial Agents
15. Cold and Cough Agents
16. Selected Agents of Pulmonary Value
17. Neonatal and Pediatric Aerosolized Drug Therapy
Unit III: Critical Care, Cardiovascular, and Polysomnography Agents
18. Skeletal Muscle Relaxants (Neuromuscular Blocking Agents)
19. Diuretic Agents
20. Drugs Affecting the Central Nervous System
21. Vasopressors, Inotropes, and Antiarrythmic Agents
22. Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics
23. Sleep and Sleep Pharmacology
,Chapter 01: Introduction to Respiratory Care Pharmacology
Gardenhire: Rau’s Respiratory Care Pharmacology, 11th Edition
MULTIPLE CHOICE
1. What is the name of the receptor sites that are located in the peripheral vasculature, the heart, bronchial
muscle, and bronchial blood vessels?
a. Beta 2 receptors c. Alpha receptors
b. Gamma receptors d. Beta 1 receptors
ANS: C
Alpha receptors are located in the peripheral vasculature, the heart, bronchial muscle, and bronchial
blood vessels.
PTS: 1
2. Which receptor site results in tachycardia, an increased potential for arrhythmias, and an increased
cardiac output?
a. Beta 1 receptor c. Alpha receptor
b. Beta 2 receptor d. Delta receptor
ANS: A
Stimulation of the beta-1 receptors results in tachycardia, an increased potential for arrhythmias, and
an increased cardiac output. In administering drugs to the pulmonary system, stimulation of the beta-1
sites is not desired. However, most respiratory pharmacologic agents have some beta-1 stimulatory
effect.
PTS: 1
3. Stimulation of the beta 2 receptors causes
a. peripheral vasoconstriction and mild bronchoconstriction in the lungs.
b. tachycardia, an increased potential for arrhythmias, and an increased cardiac output.
c. bronchodilation.
d. peripheral vasodilation, bradycardia, and decreased cardiac output.
ANS: C
Stimulation of the beta-2 receptors in the lungs causes bronchodilation.
PTS: 1
4. Acetylcholine stimulates
a. the Vagus nerve.
b. the adrenergic receptors.
c. the sympathetic nervous system.
d. the cholinergic receptors.
ANS: D
Acetylcholine stimulates the cholinergic receptors.
PTS: 1
5. What immunoglobulin antibody sensitizes the mast cell?
a. Leukotrienes c. Histamine
, b. IgE d. Prostaglandins
ANS: B
The IgE (reagin) antibodies sensitize the mast cell. Repeated exposure to the antigen causes the
degranulation of the mast cell.
PTS: 1
6. Which of the following is caused by histamine release from the mast cells?
I. Bronchodilation
II. Increased bronchial gland secretion
III. Increased amount of mucus present in the airways
a. I and II only c. III only
b. II and III only d. I, II, III
ANS: B
Histamine is also a potent bronchoconstrictor. In addition to its bronchoconstrictive activity, histamine
II) increases bronchial gland secretion, causing III) an increase in the amount of mucus present
in the airways. Histamine may also have an effect on vascular permeability similar to the effect of-
SRS-A.
PTS: 1
7. A sympathomimetic drug would cause
a. bronchodilation. c. Histamine release.
b. bronchoconstriction. d. Vagus nerve stimulation.
ANS: A
A sympathomimetic drug would cause bronchodilation. Sympathomimetic agents are the drugs most
commonly used to reverse bronchospasm.
PTS: 1
8. Stimulation of the sympathetic nervous system causes
a. vascular permeability. c. bronchodilation.
b. decreased blood pressure. d. bronchoconstriction.
ANS: C
Sympathetic nervous system stimulation causes bronchodilation.
PTS: 1
9. Which of the following would NOT cause a bronchospasm or bronchoconstriction?
a. Leukotrienes c. Histamine
b. Beta 1 receptors d. Prostaglandins
ANS: B
Beta-1 receptors would not cause a bronchospasm or bronchoconstriction. Leukotrienes are one of
many chemical mediators released by the mast cells. Leukotrienes cause a direct, strong
bronchoconstriction. Histamine is also a potent bronchoconstrictor. Prostaglandins cause a strong
bronchospasm, especially in asthmatic patients.
PTS: 1
Rau's Respiratory Care Pharmacology 11th
Edition by Douglas S. Gardenhire.
Breathe Easy: Master Respiratory Pharmacology with the Complete Test Bank!
Elevate your respiratory therapy expertise with the Test Bank for Rau's Respiratory Care Pharmacology, 11th
Edition by Douglas S. Gardenhire. This gold-standard resource covers ALL 22 Chapters, delivering exam-ready
practice aligned with the latest FDA approvals, COVID-19 insights, and clinical connections—essential for CRT,
RRT, or NBRC TMC/HM exam success.
Stop guessing and start excelling! Our 450+ page digital PDF unleashes over 2,000 questions in NBRC-style formats:
multiple-choice, true/false, calculations, and case-based scenarios that test real-world application. From foundational
principles in Unit I (Chapters 1-5: Introduction to Pharmacology, Drug Actions, Aerosol Delivery, Dose Calculations,
and Nervous Systems) to core respiratory treatments in Unit II (Chapters 6-12: Bronchodilators, Anticholinergics,
Corticosteroids, Mucokinetics, and more) and critical care in Unit III (Chapters 13-22: Sedatives, Analgesics,
Antihypertensives, Antimicrobials, and Neonatal/Pediatric Drugs), every section sharpens your skills. Each question
includes detailed rationales, correct/incorrect explanations, and page references to clarify complex topics like
surfactant therapy (Chapter 21) or neuromuscular blockers (Chapter 19).
,Description
Test Bank for Rau’s Respiratory Care Pharmacology 11th Edition Gardenhire
Test Bank for Rau’s Respiratory Care Pharmacology, 11th Edition, Gardenhire, ISBN-
10:0323871550, ISBN-13: 978-0323871556
Table of Contents
Unit I: Basic Concepts and Principles in Pharmacology
1. Introduction to Respiratory Care Pharmacology
2. Principles of Drug Action
3. Administration of Aerosolized Agents
4. Calculating Drug Doses
5. The Central and Peripheral Nervous Systems
Unit II: Drugs Used to Treat the Respiratory System
6. Adrenergic (Sympathomimetic) Bronchodilators
7. Anticholinergic (Parasympatholytic) Bronchodilators
8. Xanthines
9. Mucus-Controlling Drug Therapy
10. Surfactant Agents
11. Corticosteriods in Respiratory Care
12. Nonsteroidal Antiasthma Agents
13. Aerosolized Antiinfective Agents
14. Antimicrobial Agents
15. Cold and Cough Agents
16. Selected Agents of Pulmonary Value
17. Neonatal and Pediatric Aerosolized Drug Therapy
Unit III: Critical Care, Cardiovascular, and Polysomnography Agents
18. Skeletal Muscle Relaxants (Neuromuscular Blocking Agents)
19. Diuretic Agents
20. Drugs Affecting the Central Nervous System
21. Vasopressors, Inotropes, and Antiarrythmic Agents
22. Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics
23. Sleep and Sleep Pharmacology
,Chapter 01: Introduction to Respiratory Care Pharmacology
Gardenhire: Rau’s Respiratory Care Pharmacology, 11th Edition
MULTIPLE CHOICE
1. What is the name of the receptor sites that are located in the peripheral vasculature, the heart, bronchial
muscle, and bronchial blood vessels?
a. Beta 2 receptors c. Alpha receptors
b. Gamma receptors d. Beta 1 receptors
ANS: C
Alpha receptors are located in the peripheral vasculature, the heart, bronchial muscle, and bronchial
blood vessels.
PTS: 1
2. Which receptor site results in tachycardia, an increased potential for arrhythmias, and an increased
cardiac output?
a. Beta 1 receptor c. Alpha receptor
b. Beta 2 receptor d. Delta receptor
ANS: A
Stimulation of the beta-1 receptors results in tachycardia, an increased potential for arrhythmias, and
an increased cardiac output. In administering drugs to the pulmonary system, stimulation of the beta-1
sites is not desired. However, most respiratory pharmacologic agents have some beta-1 stimulatory
effect.
PTS: 1
3. Stimulation of the beta 2 receptors causes
a. peripheral vasoconstriction and mild bronchoconstriction in the lungs.
b. tachycardia, an increased potential for arrhythmias, and an increased cardiac output.
c. bronchodilation.
d. peripheral vasodilation, bradycardia, and decreased cardiac output.
ANS: C
Stimulation of the beta-2 receptors in the lungs causes bronchodilation.
PTS: 1
4. Acetylcholine stimulates
a. the Vagus nerve.
b. the adrenergic receptors.
c. the sympathetic nervous system.
d. the cholinergic receptors.
ANS: D
Acetylcholine stimulates the cholinergic receptors.
PTS: 1
5. What immunoglobulin antibody sensitizes the mast cell?
a. Leukotrienes c. Histamine
, b. IgE d. Prostaglandins
ANS: B
The IgE (reagin) antibodies sensitize the mast cell. Repeated exposure to the antigen causes the
degranulation of the mast cell.
PTS: 1
6. Which of the following is caused by histamine release from the mast cells?
I. Bronchodilation
II. Increased bronchial gland secretion
III. Increased amount of mucus present in the airways
a. I and II only c. III only
b. II and III only d. I, II, III
ANS: B
Histamine is also a potent bronchoconstrictor. In addition to its bronchoconstrictive activity, histamine
II) increases bronchial gland secretion, causing III) an increase in the amount of mucus present
in the airways. Histamine may also have an effect on vascular permeability similar to the effect of-
SRS-A.
PTS: 1
7. A sympathomimetic drug would cause
a. bronchodilation. c. Histamine release.
b. bronchoconstriction. d. Vagus nerve stimulation.
ANS: A
A sympathomimetic drug would cause bronchodilation. Sympathomimetic agents are the drugs most
commonly used to reverse bronchospasm.
PTS: 1
8. Stimulation of the sympathetic nervous system causes
a. vascular permeability. c. bronchodilation.
b. decreased blood pressure. d. bronchoconstriction.
ANS: C
Sympathetic nervous system stimulation causes bronchodilation.
PTS: 1
9. Which of the following would NOT cause a bronchospasm or bronchoconstriction?
a. Leukotrienes c. Histamine
b. Beta 1 receptors d. Prostaglandins
ANS: B
Beta-1 receptors would not cause a bronchospasm or bronchoconstriction. Leukotrienes are one of
many chemical mediators released by the mast cells. Leukotrienes cause a direct, strong
bronchoconstriction. Histamine is also a potent bronchoconstrictor. Prostaglandins cause a strong
bronchospasm, especially in asthmatic patients.
PTS: 1
